Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · December 30, 2023

Divarasib Plus Cetuximab for KRAS G12C–Positive Colorectal Cancer

Nature Medicine


Additional Info

Nature Medicine
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
Nat. Med. 2023 Dec 05;[EPub Ahead of Print], J Desai, G Alonso, SH Kim, A Cervantes, T Karasic, L Medina, E Shacham-Shmueli, R Cosman, A Falcon, E Gort, T Guren, E Massarelli, WH Miller, L Paz-Ares, H Prenen, A Amatu, C Cremolini, TW Kim, V Moreno, SI Ou, A Passardi, A Sacher, A Santoro, R Stec, S Ulahannan, K Arbour, P Lorusso, J Luo, MR Patel, Y Choi, Z Shi, S Mandlekar, MT Lin, S Royer-Joo, J Chang, T Jun, NV Dharia, JL Schutzman, SW Han

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading